Federal update: DOJ partially rescheduled medical cannabis to Schedule III (April 28, 2026 final order). State-licensed medical operators may apply for expedited DEA registration through June 27, 2026; DEA hearing on full rescheduling set for June 29, 2026.
Your complete guide to cannabis in the Volunteer State Official TABC / TDA / TMCC data · No product sales · TryCannabis.org

TACIR Medical-Cannabis Readiness Study

In April 2026, the Tennessee General Assembly authorized a second medical-cannabis study layered on top of the existing study commission. SB 1603 — signed by Gov. Bill Lee on April 23, 2026 — directed the Tennessee Advisory Commission on Intergovernmental Relations (TACIR) to study state and local government "operational readiness" for a medical cannabis program and report by November 1, 2026. The same bill stripped the Health and Mental Health/Substance Abuse Services commissioners of authority to align state cannabis scheduling with federal rescheduling without legislative approval. Reform advocates view the TACIR layer as a deferral mechanism; supporters frame it as essential due-diligence for an eventual program.

Last verified: May 2026

What SB 1603 Does

Senate Bill 1603, sponsored by Sen. Andrew Farmer (R-Sevierville), was signed into law by Gov. Bill Lee on April 23, 2026. The bill has two distinct operative parts:

  1. Anti-rescheduling provision. The bill expressly strips the Tennessee Department of Health Commissioner and the Tennessee Department of Mental Health and Substance Abuse Services Commissioner of statutory authority to align Tennessee’s controlled-substances scheduling with federal rescheduling without affirmative legislative approval. This blocks any administrative pathway by which the December 2025 federal Schedule III order could automatically translate into a Tennessee state-law change.
  2. TACIR study referral. The bill directs the Tennessee Advisory Commission on Intergovernmental Relations (TACIR) to study state and local government "operational readiness" for a medical cannabis program and report by November 1, 2026.

Sen. Ferrell Haile (R-Gallatin) sponsored the related TACIR-readiness-study referral language enacted alongside SB 1603.

What TACIR Is

The Tennessee Advisory Commission on Intergovernmental Relations (TACIR) is a research and advisory body established to monitor the operations of intergovernmental relationships among state and local government in Tennessee, recommending changes to enhance coordination. TACIR is staffed by professional researchers, has a track record of producing methodologically rigorous reports, and is generally treated as a credible institutional voice within the General Assembly.

For cannabis policy, the TACIR brief is unusual: TACIR is being asked to study whether state and local government in Tennessee are "operationally ready" to implement a medical-cannabis program — not whether such a program is desirable, not what its scope should be, not who should regulate it. The framing is administrative-readiness, not policy advocacy.

The TACIR Study Brief

Per SB 1603, the TACIR study is to address state and local government "operational readiness." Read narrowly, this could include:

  • Regulatory infrastructure: which agency would have lead jurisdiction (Tennessee Department of Health? Tennessee Department of Agriculture? Tennessee Alcoholic Beverage Commission? a new commission?); rule-making capacity; staffing requirements; budget needs.
  • Patient registry and physician certification: database design, identity verification, physician opt-in mechanics, qualifying-condition adjudication.
  • Local-government capacity: zoning, local opt-in/opt-out, law-enforcement coordination, drug-recognition training, public-health coordination.
  • Budget and revenue: licensing-fee structure, regulatory cost recovery, sales-tax interaction with the existing 7% state plus local-option (up to 2.75%) sales-tax framework, the new HDCP wholesale taxes under Public Chapter 526.
  • Federal interaction: Schedule III implications for in-state cultivation, FDA prescribing implications post-rescheduling, cross-state-line transport.

Layering on Top of the TMCC

The notable structural fact: the Tennessee Medical Cannabis Commission (TMCC), created by 2021 Public Acts Chapter 577 and codified at T.C.A. §§ 68-7-101 to 68-7-104, has been studying medical-cannabis-program design since 2021 and has produced multiple annual reports recommending a "safe harbor" framework, a "Master Medical Cannabis Program Outline," and various operational specifics. Public Chapter 50 of 2025 extended the TMCC sunset to June 30, 2029. See TMCC page.

The TACIR layer is a second study, bringing a different institutional voice (intergovernmental-relations researchers rather than appointed commissioners), but addressing similar territory. Reform advocates — including Marijuana Policy Project, TN NORML, the Tennessee Medical Cannabis Trade Association (TMCTA), the Tennessee Medical Cannabis Alliance (TMCA), and the Drug Policy Reform Coalition of Tennessee — characterize this as a deferral mechanism: the TMCC’s recommendations have not been adopted, so a second study extends the wait without resolving the underlying policy question. Rep. Jason Powell (D-Nashville) publicly called for a cannabis special session in April 2026 in response: "For years, Tennesseans have been told to wait. We created a commission. We studied the issue. ... At some point, we have to be willing to act."

The Anti-Rescheduling Provision and Federal Schedule III

The other half of SB 1603 is structurally distinct from the study referral. President Trump’s December 2025 executive order moved cannabis to federal Schedule III — a substantial federal regulatory change but one that does not, by itself, alter state controlled-substances law. SB 1603 expressly closes off any administrative pathway by which Tennessee health agencies could align state scheduling with the federal change, leaving rescheduling as a question that must be resolved by the General Assembly through enacted legislation. The statute reflects a leadership posture that any state-law cannabis change must come through legislative action, not executive or commissioner discretion.

What the November 1, 2026 Report Will and Will Not Resolve

What the report can address:

  • Specific operational and budgetary requirements for a Tennessee medical-cannabis program.
  • Staffing, IT, and rule-making capacity gaps.
  • Local-government readiness assessment.
  • Regulatory architecture options (lead-agency choice, license categories, vertical integration).

What the report cannot resolve:

  • Whether the General Assembly should pass a medical-cannabis program. That is a policy question reserved to elected legislators.
  • Federal-state legal conflict in the absence of full federal descheduling.
  • The political dynamics of the Republican supermajority (75+ House / 27 Senate) that has, session after session, declined to advance comprehensive medical bills.

Practical Implication for the 2027 Session

If TACIR delivers its report by November 1, 2026, the 2027 General Assembly session (convening January 2027) will have, for the first time, both:

  • A multi-year TMCC body of work (2022, 2023, 2024, and 2025 annual reports plus likely a 2026 report).
  • An institutional TACIR readiness assessment.

That structural pairing — combined with continued cross-border tax loss visibility, the maturing Kentucky medical program, the contracting hemp market under Public Chapter 526, and federal Schedule III implementation pressure — may shift the leadership calculus, but no commitment to do so has been made by Gov. Lee, Lt. Gov. McNally, or Speaker Sexton. The 2024 Vanderbilt Poll documented 63% recreational-legalization support and 81% medical-cannabis-decision support. See Vanderbilt Poll page.

For in-depth cannabis education, dosing guides, safety information, and research summaries, visit our partner site TryCannabis.org